Sinovac Biotech Ltd
- Close
- Jun 30, 2026
- Market cap
- $464.93M
- 71.86M shares
- Filings
- 578
FY 2025+6.8% FY25 yoy
FY 2025N/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025+45.6% FY25 yoy
- $464.93M
- —
- 1.2×
- 0.1×
- -120.68%
- 760.19%
FY2025 figures · derived
Price
Jun 30, 2026 · 13F quarter end
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $386,013,000 | reported | |
| FY 2024 | 2024-12-31 | $361,374,000 | reported | |
| FY 2023 | 2023-12-31 | $470,170,000 revised | reported | |
| FY 2022 | 2022-12-31 | $1,473,427,000 revised | reported | |
| FY 2021 | 2021-12-31 | $19,365,354,000 revised | reported | |
| FY 2020 | 2020-12-31 | $510,624,000 | reported | |
| FY 2019 | 2019-12-31 | $246,053,000 | reported | |
| FY 2018 | 2018-12-31 | $229,650,000 | reported | |
| FY 2017 | 2018-01-01 | $3,888,000 | reported | |
| FY 2016 | 2016-12-31 | $72,431,000 | reported | |
| FY 2015 | 2015-12-31 | $67,414,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $3.53B | — | $3.53B | $55.00 | 71.86M sh | ±0.0% | — |
| FY2024 | $947.00M | — | $947.00M | — | 71.86M sh | −27.9% | — |
| FY2023 | $328.08M | — | $328.08M | — | 99.64M sh | +0.1% | — |
| FY2022 | $247.40M | — | $247.40M | — | 99.50M sh | ±0.0% | — |
| FY2021 | $1.88B | — | $1.88B | — | 99.50M sh | +0.2% | 12.7% |
Segments
Geography
LineFY2025ShareChange
PRC$261.18M68%−12.1%
Outside Chinese Mainland$124.83M32%+93.9%
Outside Mainland China———
Total$386.01M
Pharmaceutical preparations
Sinovac Biotech Ltd is the 62nd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ZLABZai Lab Ltd$460.2M15.3%38.1%$29.3BARWRArrowhead Pharmaceuticals, Inc.$450.8M45.6%160.6%$6.7BINVAInnoviva, Inc.$411.3M14.7%65.9%$1.3BARDXArdelyx, Inc.$407.3M22.1%15.1%$781.8M
SVASinovac Biotech Ltd (this company)$386.0M6.8%51.5%$464.9M
PHARPharming Group N.V.$376.1M26.6%0.8%$922.0MARQTArcutis Biotherapeutics, Inc.$376.1M91.3%4.3%$3.3BMNKDMannkind Corp$349.0M22.2%1.7%$1.3BCRMDCorMedix Inc.$311.7M617.0%52.3%$427.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Sinovac Biotech Ltd · CIK 1084201 · Engraved from SEC EDGAR